Pharming Group (OTCMKTS:PHGUF) Shares Gap Down – Here’s What Happened

Pharming Group NV (OTCMKTS:PHGUF)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $1.28, but opened at $1.18. Pharming Group shares last traded at $1.18, with a volume of 10,000 shares traded.

Pharming Group Stock Down 7.8%

The company has a debt-to-equity ratio of 0.39, a current ratio of 2.59 and a quick ratio of 2.03. The business has a 50 day simple moving average of $1.49 and a 200 day simple moving average of $1.62. The company has a market capitalization of $791.86 million, a price-to-earnings ratio of 59.03 and a beta of 0.45.

Pharming Group (OTCMKTS:PHGUF) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) EPS for the quarter. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.